Patrick Gray, CEO and Director, acquired 842,975 Common Shares on a direct ownership basis at a price of $0.200 through a prospectus or prospectus exempt offering on November 30th, 2020. This represents a $168,595 investment into the company's shares and an account share holdings change of greater than 100%.
One other insider also participated in the deal in a smaller amount.
Pascal Biosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Pascal Biosciences Inc, formerly Biommune Technologies Inc, is a Canada-based biopharmaceutical company. The Company is a research and development issuer. The Company is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The Company operates in the segment of biotechnology research and development. The Company focuses on cancer, infectious and autoimmune diseases. It offers various technologies, such as Major Histocompatibility Complex I (MHC I), a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells, where the fragments are then exposed to the immune system's T Cells; CD74, a chaperone protein that is involved in the presentation of MHC I and MHC II molecules on cell surfaces, and Calcium Channel Blockers, which are methods and agents that modulate voltage-gated calcium channels.
No Comments